Syros Pharmaceuticals, Inc. (SYRS)
After hours:
| Previous close | 5.48 |
| Open | 5.36 |
| Bid | 5.40 x 100 |
| Ask | 5.47 x 100 |
| Day's range | 5.29 - 5.52 |
| 52-week range | 2.09 - 8.17 |
| Volume | |
| Avg. volume | 196,703 |
| Market cap | 145.669M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
CAMBRIDGE, Mass., May 14, 2024--Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today reported financial results for the quarter ended March 31, 2024 and provided a corporate update.
- Business Wire
Syros to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., May 07, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that company management will participate in a fireside chat at two upcoming investor conferences. Details are as follows:
- Business Wire
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
CAMBRIDGE, Mass., May 07, 2024--Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, May 14, 2024 to report its first quarter 2024 financial results and provide a corporate update.
